Microbix Biosystems Inc. (TSX:MBX; OTCQX:MBXBF) has commercialized custom biological materials intended for use in laboratory assays and point-of-care test cartridges made by in-vitro diagnostics manufacturers. The company said initial sales have been made to two diagnostics manufacturers, with each incorporating a Microbix material into a new assay or assays.
#Materials to be used as sample processing controls
The materials are supplied to diagnostics manufacturers for additional manufacturing before being built into finished tests as sample processing controls, or SPCs. These controls are non-target biological materials processed alongside patient samples.
When a test does not detect its target but the SPC does not work, the result is classified as invalid rather than negative. Once incorporated into an assay, the Microbix materials are intended to help verify that key steps, including nucleic-acid extraction, amplification and detection, have operated correctly.
Microbix said the new materials can support both DNA-based and RNA-based molecular assays. For RNA applications, the materials also cover the reverse-transcription step.
The company said this product class complements its QAPs™ external quality assessment products and QUANTDx™ reference materials. Microbix said all three classes can use customised nucleic-acid sequences designed around the targeting requirements of diagnostics manufacturers.
Microbix said it expects to generate recurring sales to the two initial diagnostics-manufacturer customers and expects to secure additional customers for the materials. The company said sales of the category are targeted to become material as customer assays are commercialized and additional customer programmes and customers are secured.
Phil Casselli, Microbix’s SVP of Sales & Business Development, said SPC-oriented materials differ from external quality assessment samples because the diagnostics manufacturer incorporates them into each test unit. External assessment samples are used periodically by clinical laboratories or may be included one per box with test cartridges, according to Casselli.
Pavel Zhelev, Microbix’s Director of Product Management, said test designs can fail for multiple reasons. He said an SPC that verifies whether each test has run correctly is needed for regulatory approvals and reimbursement, best-practice use and patient safety.
Microbix is a Canadian life sciences company whose biological products support diagnostic testing, laboratory quality assurance and disease management. The company said it has over 100 employees and reported fiscal 2025 revenues of C$18.6 million.
Microbix said its products are available in more than 30 countries through international distribution partners. Its proprietary antigens are used by approximately 100 diagnostics manufacturers, alongside its QAPs™ quality assessment products and QUANTDx™ reference materials. The company is headquartered in Mississauga, Ontario, and trades on the TSX and OTCQX.
Microbix said statements about recurring sales, additional customers and the future materiality of the product category are forward-looking information based on management’s estimates, beliefs, intentions and expectations. The company cautioned that these statements are not guarantees of future performance and that actual events, conditions and results may differ materially.
Risks identified by Microbix include regulatory compliance and approvals, sales in foreign jurisdictions, production controls, currency exchange rates, working capital and the ability to raise capital on acceptable terms or at all.
Microbix has commercialized custom biologic materials for incorporation into diagnostic assays and point-of-care test cartridges.
Initial sales have been made to two diagnostics manufacturers, each using a Microbix material in a new assay or assays.
The materials are designed for use as sample processing controls in DNA- and RNA-based molecular tests.
Microbix expects recurring sales and additional customers, while stating that future sales materiality depends on assay commercialization and further customer programmes.
Microbix Biosystems Inc. announced that it has commercialized custom biological materials for incorporation into the laboratory-based assays or point-of-care test cartridges of in-vitro diagnostics manufacturers. The company said initial sales had been made to two such manufacturers, with each incorporating a Microbix biologic material into a new assay or assays.
The materials are supplied to diagnostics manufacturers for further manufacturing and later incorporation into finished assays as sample processing controls, or SPCs. SPCs are known non-target biological materials processed with each patient sample to help confirm that critical stages of a molecular assay are functioning.
If a test target is not detected and the SPC fails, the test is reported as invalid rather than negative. Once incorporated into an assay, the materials help confirm that nucleic-acid extraction, amplification and detection are each functioning.
Microbix Biosystems Inc. said initial sales had been made to two diagnostics manufacturers. Each is incorporating a Microbix biologic material into a new assay or assays.
Microbix Biosystems Inc. expects to generate recurring sales to the two initial diagnostics-manufacturer customers and expects that additional customers will be secured for these products. The company said sales of the new category are targeted to become material as client assays are commercialized and as further client programmes and clients are secured.
Yes. Microbix Biosystems Inc. said it can provide the materials for both DNA- and RNA-based molecular assays, with the RNA-oriented materials also covering the reverse-transcription step.
Microbix Biosystems Inc. said the DNA- and RNA-oriented biologic materials complement its QAPs™ external quality assessment products and QUANTDx™ reference materials. Each of the three product classes can incorporate customised nucleic-acid sequences designed to meet diagnostics manufacturers' targeting needs.
Phil Casselli, Microbix Biosystems Inc.'s SVP of Sales & Business Development, said the SPC-oriented materials are built into each test unit by the diagnostics manufacturer, unlike external quality assessment samples used periodically by clinical laboratories or included one-per-box with test cartridges. He said adding the category rounds out the portfolio and supports the company's Customer Success philosophy across diagnostic assay development, manufacturing and usage.
Pavel Zhelev, Microbix Biosystems Inc.'s Director of Product Management, said test designs can be vulnerable to failure from many different causes. He said an SPC that confirms each test has run correctly is necessary for regulatory approvals and reimbursement, best-practice usage and patient safety.
Microbix Biosystems Inc. is a Canadian life sciences company working to advance global health through biological products supporting diagnostic testing, laboratory quality assurance and disease management. Its products include proprietary antigens, QAPs™ quality assessment products, QUANTDx™ reference materials, and reagents for test-sample collection or processing.
Microbix Biosystems Inc. said it has over 100 employees and reported fiscal 2025 revenues of C$18.6 million. The company said its products are available in more than 30 countries through international distribution partners and that its proprietary antigens are used by approximately 100 diagnostics manufacturers.
Microbix Biosystems Inc. said it trades on the TSX under TSX:MBX and on the OTCQX under OTCQX:MBXBF.
Microbix Biosystems Inc. said its forward-looking information reflects management's current estimates, beliefs, intentions and expectations and is not a guarantee of future performance. The company cautioned that actual events, conditions and results may differ materially because of factors including regulatory compliance and approvals, access to and sales in foreign jurisdictions, production controls, currency exchange rates, working capital and the ability to raise capital on acceptable terms or at all.